WO2013190292A3 - Novel process for preparation of antibody conjugates and novel antibody conjugates - Google Patents
Novel process for preparation of antibody conjugates and novel antibody conjugates Download PDFInfo
- Publication number
- WO2013190292A3 WO2013190292A3 PCT/GB2013/051593 GB2013051593W WO2013190292A3 WO 2013190292 A3 WO2013190292 A3 WO 2013190292A3 GB 2013051593 W GB2013051593 W GB 2013051593W WO 2013190292 A3 WO2013190292 A3 WO 2013190292A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody conjugates
- novel
- preparation
- disulfide bond
- novel process
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (36)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112014031613A BR112014031613A2 (en) | 2012-06-19 | 2013-06-19 | process for preparing antibody conjugates and antibody conjugates |
CA 2876365 CA2876365A1 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
AU2013279099A AU2013279099A1 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
CN201380032701.7A CN104379178A (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
IN10428DEN2014 IN2014DN10428A (en) | 2012-06-19 | 2013-06-19 | |
EP13731444.9A EP2861261A2 (en) | 2012-06-19 | 2013-06-19 | Process for preparation of antibody conjugates and antibody conjugates |
JP2015517843A JP2015521615A (en) | 2012-06-19 | 2013-06-19 | Novel method for the preparation of antibody conjugates and novel antibody conjugates |
MX2014015682A MX2014015682A (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates. |
US14/407,859 US20150125473A1 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
RU2015101333A RU2015101333A (en) | 2012-06-19 | 2013-06-19 | A NEW METHOD FOR OBTAINING ANTIBODIES CONJUGATES AND NEW ANTIBODIES CONJUGATES |
SG11201407600UA SG11201407600UA (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
KR20157001179A KR20150023027A (en) | 2012-06-19 | 2013-06-19 | Novel Process for Preparation of Antibody Conjugates and Novel Antibody Conjugates |
DK13786530.9T DK2911700T5 (en) | 2012-10-24 | 2013-10-11 | The drug-protein conjugates |
JP2015538560A JP6328648B2 (en) | 2012-10-24 | 2013-10-11 | Novel drug-protein conjugates |
CA2884299A CA2884299A1 (en) | 2012-10-24 | 2013-10-11 | Novel drug-protein conjugates |
MYPI2015701285A MY169147A (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
BR112015008376A BR112015008376A2 (en) | 2012-10-24 | 2013-10-11 | drug-protein conjugates |
AU2013336409A AU2013336409B2 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
RU2015119561A RU2015119561A (en) | 2012-10-24 | 2013-10-11 | NEW CONJUGATES MEDICINE-PROTEIN |
CN201380055880.6A CN104870021B (en) | 2012-10-24 | 2013-10-11 | Pharmaceutical protein conjugate |
US14/437,537 US20150290342A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
EP16203350.0A EP3159013A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
PCT/GB2013/052661 WO2014064423A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
MX2015005122A MX2015005122A (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates. |
SG11201501618WA SG11201501618WA (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
ES13786530.9T ES2623209T3 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
EP13786530.9A EP2911700B1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
IN2349DEN2015 IN2015DN02349A (en) | 2012-10-24 | 2013-10-11 | |
KR1020157011427A KR102209395B1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
IL235646A IL235646A0 (en) | 2012-06-19 | 2014-11-11 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
ZA2014/08916A ZA201408916B (en) | 2012-06-19 | 2014-12-04 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
ZA2015/01642A ZA201501642B (en) | 2012-10-24 | 2015-03-10 | Drug-protein conjugates |
IL237672A IL237672B (en) | 2012-10-24 | 2015-03-11 | Drug-protein conjugates |
HK15105477.4A HK1204924A1 (en) | 2012-06-19 | 2015-06-09 | Process for preparation of antibody conjugates and antibody conjugates |
HK15108932.7A HK1208187A1 (en) | 2012-10-24 | 2015-09-11 | Drug protein conjugates |
US17/477,565 US20220062436A1 (en) | 2012-10-24 | 2021-09-17 | Drug-protein conjugates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1210838.7 | 2012-06-19 | ||
GBGB1210838.7A GB201210838D0 (en) | 2012-06-19 | 2012-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
GB1306706.1 | 2013-04-12 | ||
GB201306706A GB201306706D0 (en) | 2013-04-12 | 2013-04-12 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/052661 Continuation-In-Part WO2014064423A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
US14/437,537 Continuation-In-Part US20150290342A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013190292A2 WO2013190292A2 (en) | 2013-12-27 |
WO2013190292A3 true WO2013190292A3 (en) | 2014-03-20 |
Family
ID=48699187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/051593 WO2013190292A2 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150125473A1 (en) |
EP (1) | EP2861261A2 (en) |
JP (1) | JP2015521615A (en) |
KR (1) | KR20150023027A (en) |
CN (1) | CN104379178A (en) |
AU (1) | AU2013279099A1 (en) |
BR (1) | BR112014031613A2 (en) |
CA (1) | CA2876365A1 (en) |
HK (1) | HK1204924A1 (en) |
IL (1) | IL235646A0 (en) |
IN (1) | IN2014DN10428A (en) |
MX (1) | MX2014015682A (en) |
RU (1) | RU2015101333A (en) |
SG (1) | SG11201407600UA (en) |
WO (1) | WO2013190292A2 (en) |
ZA (1) | ZA201408916B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073131A (en) * | 2014-10-24 | 2017-08-18 | 宝力泰锐克斯有限公司 | Conjugate and conjugation reagents |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2789793T3 (en) * | 2012-10-24 | 2018-01-27 | ||
MY169147A (en) * | 2012-10-24 | 2019-02-18 | Polytherics Ltd | Drug-protein conjugates |
BR112015022585B1 (en) | 2013-03-15 | 2023-04-04 | Regeneron Pharmaceuticals, Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, DRUG-ANTIBOD CONJUGATE, AND USE THEREOF |
AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
US10406198B2 (en) | 2014-05-23 | 2019-09-10 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
EP3148592A2 (en) * | 2014-06-02 | 2017-04-05 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
CA2955007C (en) * | 2014-07-24 | 2023-04-11 | Genentech, Inc. | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
MA40725A (en) * | 2014-12-08 | 2017-10-18 | Sorrento Therapeutics Inc | ANTI-C-MET-DRUG ANTIBODY CONJUGATE |
CA2973355A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
CN107667113B (en) * | 2015-02-05 | 2022-05-03 | 埃博灵克斯股份有限公司 | Cysteine-linked nanobody dimers engineered through the C-terminus |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
US10233212B2 (en) | 2015-11-03 | 2019-03-19 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
MA43094B1 (en) | 2016-01-25 | 2020-10-28 | Regeneron Pharma | Maytansinoid derivatives, their conjugates, and methods of use |
WO2017178828A1 (en) * | 2016-04-14 | 2017-10-19 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
CA3041533A1 (en) * | 2016-11-07 | 2018-05-11 | Seattle Genetics, Inc. | Distribution of engineered-cysteine caps |
CN112020519A (en) * | 2018-03-13 | 2020-12-01 | 酵活有限公司 | anti-HER 2 biparatopic antibody-drug conjugates and methods of use |
GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
CN113423730B (en) | 2019-02-15 | 2024-01-05 | 上海药明合联生物技术有限公司 | Method for preparing antibody-drug conjugates with improved homogeneity |
US20220098242A1 (en) * | 2020-02-26 | 2022-03-31 | University Of Maryland, College Park | Compositions and methods for mucosal vaccination against sars-cov-2 |
CN113164621B (en) * | 2020-12-08 | 2022-02-18 | 和铂医药(上海)有限责任公司 | Protein-drug conjugates and site-directed conjugation methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007197A2 (en) * | 2003-07-11 | 2005-01-27 | Polytherics Limited | Conjugated biological molecules and their preparation |
WO2009099728A1 (en) * | 2008-01-31 | 2009-08-13 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2009130602A2 (en) * | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
WO2011060018A2 (en) * | 2009-11-13 | 2011-05-19 | Ikaria Development Subsidiary Two Llc | Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008521828A (en) * | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | Engineered antibodies and immunoconjugates |
US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
US20120201746A1 (en) * | 2010-12-22 | 2012-08-09 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
-
2013
- 2013-06-19 MX MX2014015682A patent/MX2014015682A/en unknown
- 2013-06-19 RU RU2015101333A patent/RU2015101333A/en not_active Application Discontinuation
- 2013-06-19 US US14/407,859 patent/US20150125473A1/en not_active Abandoned
- 2013-06-19 CA CA 2876365 patent/CA2876365A1/en not_active Abandoned
- 2013-06-19 BR BR112014031613A patent/BR112014031613A2/en not_active IP Right Cessation
- 2013-06-19 JP JP2015517843A patent/JP2015521615A/en active Pending
- 2013-06-19 AU AU2013279099A patent/AU2013279099A1/en not_active Abandoned
- 2013-06-19 SG SG11201407600UA patent/SG11201407600UA/en unknown
- 2013-06-19 CN CN201380032701.7A patent/CN104379178A/en active Pending
- 2013-06-19 EP EP13731444.9A patent/EP2861261A2/en not_active Withdrawn
- 2013-06-19 IN IN10428DEN2014 patent/IN2014DN10428A/en unknown
- 2013-06-19 KR KR20157001179A patent/KR20150023027A/en not_active Application Discontinuation
- 2013-06-19 WO PCT/GB2013/051593 patent/WO2013190292A2/en active Application Filing
-
2014
- 2014-11-11 IL IL235646A patent/IL235646A0/en unknown
- 2014-12-04 ZA ZA2014/08916A patent/ZA201408916B/en unknown
-
2015
- 2015-06-09 HK HK15105477.4A patent/HK1204924A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007197A2 (en) * | 2003-07-11 | 2005-01-27 | Polytherics Limited | Conjugated biological molecules and their preparation |
WO2009099728A1 (en) * | 2008-01-31 | 2009-08-13 | Genentech, Inc. | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2009130602A2 (en) * | 2008-04-24 | 2009-10-29 | Celtic Pharma Peg Ltd. | Factor ix conjugates with extended half-lives |
WO2011060018A2 (en) * | 2009-11-13 | 2011-05-19 | Ikaria Development Subsidiary Two Llc | Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives |
Non-Patent Citations (7)
Title |
---|
BILDSTEIN L ET AL: "Prodrug-based intracellular delivery of anticancer agents", ADVANCED DRUG DELIVERY REVIEWS, vol. 63, no. 1, 21 December 2010 (2010-12-21), pages 3 - 23, XP028371427, ISSN: 0169-409X, [retrieved on 20110113], DOI: 10.1016/J.ADDR.2010.12.005 * |
BROCCHINI STEVE ET AL: "PEGylation of native disulfide bonds in proteins", NATURE PROTOCOLS, vol. 1, no. 5, 2006, pages 2241 - 2252, XP001539596, ISSN: 1750-2799, DOI: 10.1038/NPROT.2006.346 * |
JAGATH R JUNUTULA ET AL: "Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index", NATURE BIOTECHNOLOGY, vol. 26, no. 8, August 2008 (2008-08-01), pages 925 - 932, XP002623992, ISSN: 1087-0156, [retrieved on 20080720], DOI: 10.1038/NBT.1480 * |
LEWIS A ET AL: "Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation", BIOCONJUGATE CHEMISTRY, vol. 19, no. 11, November 2008 (2008-11-01), pages 2144 - 2155, XP002544347, ISSN: 1043-1802, [retrieved on 20081031], DOI: 10.1021/BC800242T * |
SHAUNAK SUNIL ET AL: "Site-specific PEGylation of native disulfide bonds in therapeutic proteins", NATURE CHEMICAL BIOLOGY, vol. 2, no. 6, June 2006 (2006-06-01), pages 312 - 313, XP002544349, ISSN: 1552-4450, [retrieved on 20060423], DOI: 10.1038/NCHEMBIO786 * |
SUNIL SHAUNAK ET AL: "Supplementary Methods", 2006, XP055097811, Retrieved from the Internet <URL:http://www.nature.com/nchembio/journal/v2/n6/extref/nchembio786-S1.pdf> [retrieved on 20140122] * |
SUNIL SHAUNAK ET AL: "Supplementary Results 5", 2006, XP055097812, Retrieved from the Internet <URL:http://www.nature.com/nchembio/journal/v2/n6/extref/nchembio786-S6.pdf> [retrieved on 20140122] * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107073131A (en) * | 2014-10-24 | 2017-08-18 | 宝力泰锐克斯有限公司 | Conjugate and conjugation reagents |
CN107073131B (en) * | 2014-10-24 | 2021-05-25 | 宝力泰锐克斯有限公司 | Conjugates and conjugation reagents |
Also Published As
Publication number | Publication date |
---|---|
IL235646A0 (en) | 2015-01-29 |
RU2015101333A (en) | 2016-08-10 |
AU2013279099A1 (en) | 2014-12-18 |
CN104379178A (en) | 2015-02-25 |
BR112014031613A2 (en) | 2017-07-25 |
EP2861261A2 (en) | 2015-04-22 |
IN2014DN10428A (en) | 2015-08-21 |
KR20150023027A (en) | 2015-03-04 |
SG11201407600UA (en) | 2014-12-30 |
US20150125473A1 (en) | 2015-05-07 |
CA2876365A1 (en) | 2013-12-27 |
ZA201408916B (en) | 2015-11-25 |
HK1204924A1 (en) | 2015-12-11 |
JP2015521615A (en) | 2015-07-30 |
WO2013190292A2 (en) | 2013-12-27 |
MX2014015682A (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013190292A3 (en) | Novel process for preparation of antibody conjugates and novel antibody conjugates | |
NZ701040A (en) | Covalently linked antigen-antibody conjugates | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
WO2012064733A3 (en) | Antibody scaffold for homogenous conjugation | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
MX356337B (en) | Antibodies against human csf-1r and uses thereof. | |
MX2016008189A (en) | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof. | |
WO2012016227A3 (en) | Antibodies with modified isoelectric points | |
MX336682B (en) | Antibodies against human csf-1r and uses thereof. | |
WO2011133704A3 (en) | Modified polypeptides and proteins and uses thereof | |
NZ602294A (en) | Monoclonal antibodies against c-met | |
MX347020B (en) | Antibody against the csf-1r. | |
NZ592214A (en) | Improved Interleukin-6 receptor antibody molecule | |
SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
EP3411069A4 (en) | Humanized anti-cd3 antibodies, conjugates and uses thereof | |
WO2012107416A3 (en) | Improved immunotherapy | |
NZ629072A (en) | Compositions comprising secretory - like immunoglobulins | |
WO2012047941A3 (en) | Hemagglutinin polypeptides, and reagents and methods relating thereto | |
WO2012125733A3 (en) | Antibody screening methods | |
WO2014124258A3 (en) | Specific sites for modifying antibodies to make immunoconjugates | |
NZ616382A (en) | Antibodies specific to cadherin-17 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13731444 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 235646 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2876365 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14407859 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/015682 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2015517843 Country of ref document: JP Kind code of ref document: A Ref document number: 2013279099 Country of ref document: AU Date of ref document: 20130619 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013731444 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157001179 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015101333 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014031613 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014031613 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141217 |